A newly announced collaboration between Owkin and Sanofi aims to revolutionize biopharmaceutical R&D through the integration of AI-powered agents. This multi-year agreement includes a five-year license for Owkin's K Pro platform, expanding their partnership that began in 2021 with an initial investment of €90 million focused on oncology.
The partnership has evolved beyond oncology target identification and immunology drug positioning to incorporate AI-driven capabilities into various research and development workflows. Under this agreement, Owkin will lead the development of specialized AI agents tailored to meet Sanofi’s R&D needs.
These AI systems will act as intelligent assistants, autonomously managing complex tasks within drug discovery and development initiatives. By deploying these agents through K Pro, Sanofi aims to enhance its existing agentic AI infrastructure, facilitating more efficient and informed decision-making.
K Pro is a sophisticated platform that combines multimodal patient data with advanced biological AI systems. It supports the entire pharmaceutical value chain, from early-stage discovery to clinical development, while also providing competitive intelligence. This approach is designed to help teams make better-informed decisions throughout the drug development lifecycle.
Thomas Clozel, CEO and co-founder of Owkin, emphasized the importance of this collaboration, stating, “Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI.” He believes the integration of K Pro into Sanofi's operations will allow the company to fully utilize its data, accelerating better decisions in drug development.
Sanofi’s Chief Digital Officer, Emmanuel Frenehard, underscored the company's commitment to advanced AI technologies as part of its digital strategy. “Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle,” he said. Frenehard further explained that by incorporating purpose-built agentic systems into their workflows, Sanofi aims to empower its teams, enabling them to operate with increased speed, depth, and confidence in delivering impactful outcomes for patients.
This initiative aligns with Owkin's broader goal of advancing Biological Artificial Superintelligence, a concept the company believes could address the increasingly complex challenges in pharmaceutical research and development. By applying AI-driven insights, both companies are making significant strides toward a more efficient and effective drug development process that could ultimately benefit patients worldwide.
As this partnership develops, industry observers will closely monitor how effectively Owkin's AI agents can enhance Sanofi's R&D capabilities and contribute to the ongoing discussion around AI in biopharma.
The stories that move AI & crypto markets — before the market reacts.
Free. 7am ET. Five stories. 62,400 readers.
